I 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
1. 
The  applicant  Alcon  Laboratories  (UK)  Ltd.  submitted  on  08  March  2001  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Opatanol, through the centralised procedure. After agreement by the CPMP on 25 January 2001, 
this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 
2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr. Patrick Salmon 
Co-Rapporteur: 
Dr. Mark A. Ainsworth 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  17  July  1996.  The  Scientific  Advice 
pertained to parts II and IV of the dossier. 
Licensing status: 
OPATANOL/Patanol has been given a Marketing Authorisation in numerous countries, especially in 
America, from December 1996. 
New applications were filed in other countries outside the EEA. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 27 March 2001. 
The Rapporteur's first Assessment Report was circulated to all CPMP members 15 June 2001. 
The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 08 June 
2001. 
During the meeting on 24-26 July 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
26 July 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  30 
August 2001. 
The  Rapporteur  and  the  CoRapporteur  circulated  the  response  Assessment  Report  on  the 
company’s responses to the List of Questions to all CPMP members on 17 October 2001. 
During  the  CPMP  meeting  on  13-15  November  2001,  the  CPMP  agreed  on  a  List  of 
Outstanding Issues. 
During the CPMP meeting on 11-13 December 2001, outstanding issues were addressed by the 
applicant  during  a  hearing  before  the  CPMP  and  a  list  of  remaining  issues  to  be  answered  in 
writing was adopted by the CPMP. 
The company submitted the responses to the CPMP list of remaining issues on 4 January 2002. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s responses to the list of remaining issues to all CPMP members on 30 January 2002. 
During  the  meeting  on  19-21  February  2002  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to OPATANOL on 21 February 2002. 
The  CPMP  Opinion  was  forwarded  in  all  official  languages  of  the  European  Commission, 
which adopted the corresponding Decision on 17 May 2002. 
1/1 
EMEA 2004 
 
  
